This study drug is now being assessed in the Phase 2b Reτain trial (NCT06544616) enrolling participants with preclinical AD with the aim to arrest Tau pathology propagation, thus contributing to delaying, or potentially preventing, cognitive decline. This evidence concerns the gene MAPT and Alzheimer disease.